Kelly Lawrence W & Associates Inc. CA Sells 600 Shares of Gilead Sciences, Inc. $GILD

Kelly Lawrence W & Associates Inc. CA lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,069 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. Kelly Lawrence W & Associates Inc. CA’s holdings in Gilead Sciences were worth $904,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Redwood Financial Network Corp boosted its position in Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC boosted its position in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 99 shares during the last quarter. Peak Financial Advisors LLC boosted its position in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co boosted its position in Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. boosted its position in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GILD. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Finally, Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.39.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company’s stock, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock valued at $9,339,230. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Down 2.2%

Shares of GILD stock opened at $116.14 on Friday. Gilead Sciences, Inc. has a 12-month low of $75.35 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock’s 50-day moving average price is $112.41 and its 200-day moving average price is $108.90. The stock has a market capitalization of $144.11 billion, a price-to-earnings ratio of 23.14, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. The business’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.